Literature DB >> 19657559

What are the outcomes of treatment among patients with sarcopenia?

S Studenski1.   

Abstract

Treatment outcomes for clinical trials of interventions on sarcopenia depend on the goals of the intervention, especially whether the treatment is considered therapeutic or preventive. Key issues regarding outcomes are the selection of a primary outcome and options for secondary outcomes. While clinical significance and face validity are key concerns when making this determination, other factors to be incorporated into the decision include measurement characteristics, feasibility and cost, risks of missing outcomes and options for alternative strategies to determine them. Primary should be highly responsive to changes in sarcopenia and clinically important. Like many problems of aging, functional abilities, especially mobility, may be the most clinically relevant states.

Entities:  

Mesh:

Year:  2009        PMID: 19657559      PMCID: PMC4879827          DOI: 10.1007/s12603-009-0206-7

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  21 in total

1.  Measuring life-space mobility in community-dwelling older adults.

Authors:  Patricia S Baker; Eric V Bodner; Richard M Allman
Journal:  J Am Geriatr Soc       Date:  2003-11       Impact factor: 5.562

2.  Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival.

Authors:  Subashan Perera; Stephanie Studenski; Julie M Chandler; Jack M Guralnik
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-07       Impact factor: 6.053

Review 3.  Indications, labeling, and outcomes assessment for drugs aimed at improving functional status in older persons: a conversation between aging researchers and FDA regulators.

Authors:  Shalender Bhasin; Mark A Espeland; William J Evans; Luigi Ferrucci; Linda P Fried; Thomas M Gill; Marco Pahor; Stephanie Studenski; Jack Guralnik; Susan Nayfield; Sergei Romashkin; Robert Perlstein; Laurie Burke; Mary Parks
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-03-06       Impact factor: 6.053

4.  A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission.

Authors:  J M Guralnik; E M Simonsick; L Ferrucci; R J Glynn; L F Berkman; D G Blazer; P A Scherr; R B Wallace
Journal:  J Gerontol       Date:  1994-03

5.  Is lower extremity strength gain associated with improvement in physical performance and disability in frail, community-dwelling elders?

Authors:  J M Chandler; P W Duncan; G Kochersberger; S Studenski
Journal:  Arch Phys Med Rehabil       Date:  1998-01       Impact factor: 3.966

6.  A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST).

Authors:  W H Ettinger; R Burns; S P Messier; W Applegate; W J Rejeski; T Morgan; S Shumaker; M J Berry; M O'Toole; J Monu; T Craven
Journal:  JAMA       Date:  1997-01-01       Impact factor: 56.272

7.  The 6-min walk test: a quick measure of functional status in elderly adults.

Authors:  Paul L Enright; Mary Ann McBurnie; Vera Bittner; Russell P Tracy; Robert McNamara; Alice Arnold; Anne B Newman
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

8.  Improvement in usual gait speed predicts better survival in older adults.

Authors:  Susan E Hardy; Subashan Perera; Yazan F Roumani; Julie M Chandler; Stephanie A Studenski
Journal:  J Am Geriatr Soc       Date:  2007-10-03       Impact factor: 5.562

Review 9.  Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report.

Authors:  Luigi Ferrucci; Jack M Guralnik; Stephanie Studenski; Linda P Fried; Gordon B Cutler; Jeremy D Walston
Journal:  J Am Geriatr Soc       Date:  2004-04       Impact factor: 5.562

Review 10.  Accelerometers and pedometers: methodology and clinical application.

Authors:  Kirsten Corder; Søren Brage; Ulf Ekelund
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2007-09       Impact factor: 4.294

View more
  8 in total

1.  Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).

Authors:  G Abellan van Kan; J M Cderbaum; M Cesari; P Dahinden; R G Fariello; R A Fielding; B H Goodpaster; S Hettwer; M Isaac; D Laurent; J E Morley; M Pahor; D Rooks; R Roubenoff; S B Rutkove; A Shaheen; S Vamvakas; J W Vrijbloed; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-12       Impact factor: 4.075

2.  Sarcopenia with limited mobility: an international consensus.

Authors:  John E Morley; Angela Marie Abbatecola; Josep M Argiles; Vickie Baracos; Juergen Bauer; Shalender Bhasin; Tommy Cederholm; Andrew J Stewart Coats; Steven R Cummings; William J Evans; Kenneth Fearon; Luigi Ferrucci; Roger A Fielding; Jack M Guralnik; Tamara B Harris; Akio Inui; Kamyar Kalantar-Zadeh; Bridget-Anne Kirwan; Giovanni Mantovani; Maurizio Muscaritoli; Anne B Newman; Filippo Rossi-Fanelli; Giuseppe M C Rosano; Ronenn Roubenoff; Morris Schambelan; Gerald H Sokol; Thomas W Storer; Bruno Vellas; Stephan von Haehling; Shing-Shing Yeh; Stefan D Anker
Journal:  J Am Med Dir Assoc       Date:  2011-07       Impact factor: 4.669

Review 3.  Clinical trials on sarcopenia: methodological issues regarding phase 3 trials.

Authors:  Gabor Abellan van Kan; Wm Cameron Chumlea; Sophie Gillette-Guyonet; Mathieu Houles; Charlotte Dupuy; Yves Rolland; Bruno Vellas
Journal:  Clin Geriatr Med       Date:  2011-06-08       Impact factor: 3.076

4.  Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older.

Authors:  H A Bischoff-Ferrari; J E Orav; J A Kanis; R Rizzoli; M Schlögl; H B Staehelin; W C Willett; B Dawson-Hughes
Journal:  Osteoporos Int       Date:  2015-06-12       Impact factor: 4.507

Review 5.  Frailty and sarcopenia: definitions and outcome parameters.

Authors:  C Cooper; W Dere; W Evans; J A Kanis; R Rizzoli; A A Sayer; C C Sieber; J-M Kaufman; G Abellan van Kan; S Boonen; J Adachi; B Mitlak; Y Tsouderos; Y Rolland; J-Y L Reginster
Journal:  Osteoporos Int       Date:  2012-07       Impact factor: 4.507

6.  Carla Task Force on Sarcopenia: propositions for clinical trials.

Authors:  G Abellan van Kan; E André; H A Bischoff Ferrari; Y Boirie; G Onder; M Pahor; P Ritz; Y Rolland; C Sampaio; S Studenski; M Visser; B Vellas
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

7.  RISK FACTORS FOR SLOW GAIT SPEED: A NESTED CASE-CONTROL SECONDARY ANALYSIS OF THE MEXICAN HEALTH AND AGING STUDY.

Authors:  M U Pérez-Zepeda; J G González-Chavero; R Salinas-Martinez; L M Gutiérrez-Robledo
Journal:  J Frailty Aging       Date:  2015

8.  Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force.

Authors:  J Guralnik; K Bandeen-Roche; S A R Bhasin; S Eremenco; F Landi; J Muscedere; S Perera; J-Y Reginster; L Woodhouse; B Vellas
Journal:  J Frailty Aging       Date:  2020
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.